Why We Rebuilt ScreeningForCancer.org: From the 2015 Mammography Debate to the 2026 Evidence Desk
In October 2015, when the USPSTF and the American Cancer Society published conflicting breast cancer screening ages (50 vs. 45), Harvard Medical School cited ScreeningForCancer.org as a resource for patients navigating the draft recommendations. A decade later, we rebuilt this domain to solve the same underlying problem across all major cancers: translating conflicting guidelines into transparent 1,000-person outcomes.
1. What Happened in October 2015
In the autumn of 2015, American women and primary care physicians faced a jarring contradiction. The U.S. Preventive Services Task Force (USPSTF) had released draft recommendations stating that routine biennial screening mammography should begin at age 50, leaving ages 40 to 49 as a Grade C individual choice. Weeks later, the American Cancer Society (ACS) published its revised guideline in JAMA recommending that all women start at age 45 (with optional annual screening at 40). Meanwhile, the American College of Obstetricians and Gynecologists (ACOG) and the American College of Radiology (ACR) insisted on annual mammograms starting at age 40.
In its clinical commentary explaining the controversy (What do the new mammography guidelines mean for you?), Harvard Medical School pointed readers to www.screeningforcancer.org to review the Task Force's draft evidence materials.
2. How the Evidence Evolved Between 2015 and 2026
Looking back a decade later, three major epidemiological shifts reshaped the screening landscape:
- Convergence at Age 40 for Breast Cancer (2024): Driven by a steady 2% annual increase in invasive breast cancer diagnoses among women aged 40 to 49 and stark mortality disparities in Black women, the USPSTF formally upgraded women aged 40 to 49 from Grade C to Grade B in April 2024. Today, USPSTF, ACS, NCCN, and ACR all agree that screening discussions and access belong in a woman's 40s, even while debating biennial versus annual intervals.
- Convergence at Age 45 for Colorectal Cancer (2021): Birth-cohort data revealed that adults born after 1960 carried double the risk of early-onset rectal and distal colon cancer compared with prior generations, prompting both the ACS (2018) and USPSTF (2021) to lower the starting age from 50 to 45.
- The Rise of Commercial Liquid Biopsies and Whole-Body MRI: While evidence-based Grade A and B screenings remain underutilized, venture-backed full-body MRI clinics and $949 cell-free DNA blood tests now market directly to anxious healthy adults without randomized mortality proof.
3. Our Editorial Commitment
We rebuilt ScreeningForCancer.org around three strict rules: (1) always show USPSTF, ACS, NCCN, and international guidelines side by side; (2) always state absolute benefits and harms per 1,000 people screened over 10 years; and (3) expose insurance coding and false-positive traps in plain language across English, Spanish, and Chinese.